Lv2
170 积分 2021-07-21 加入
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
29天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
29天前
已完结
晚期肾透明细胞癌系统性治疗中国专家共识（2024版）
1个月前
已完结
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
3个月前
已完结
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
3个月前
已完结
Renal cell carcinoma
3个月前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
3个月前
已完结
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
4个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
4个月前
已完结
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
4个月前
已完结
皖公网安备34019202002308
